Closing Gaps in Essential Chest Pain Care Through Accreditation

David E. Winchester; Anwar Osborne; W. Frank Peacock; Deepak L. Bhatt; Gregory J. Dehmer; Deborah Diercks; Frederick A. Masoudi; James McCord; Michael Kontos; Phillip D. Levy

doi:10.1016/j.jacc.2020.03.044

Closing Gaps in Essential Chest Pain Care Through Accreditation

David E. Winchester, Anwar Osborne, W. Frank Peacock, Deepak L. Bhatt, Gregory J. Dehmer, Deborah Diercks, Frederick A. Masoudi, James McCord, Michael Kontos, Phillip D. Levy

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	2478-2482
Number of pages	5
Journal	Journal of the American College of Cardiology
Volume	75
Issue number	19
DOIs	https://doi.org/10.1016/j.jacc.2020.03.044
State	Published - May 19 2020

Keywords

accreditation
acute coronary syndrome
chest pain
quality of health care

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2020.03.044

Cite this

@article{6d775be13a9d47b1a7a7858f51f18a46,

title = "Closing Gaps in Essential Chest Pain Care Through Accreditation",

keywords = "accreditation, acute coronary syndrome, chest pain, quality of health care",

author = "Winchester, {David E.} and Anwar Osborne and Peacock, {W. Frank} and Bhatt, {Deepak L.} and Dehmer, {Gregory J.} and Deborah Diercks and Masoudi, {Frederick A.} and James McCord and Michael Kontos and Levy, {Phillip D.}",

note = "Funding Information: The authors acknowledge the significant contributions of the following persons in the development of this paper and the acquisition and interpretation of accreditation data: Raymond D. Bahr, Tammy Bauer, Robert Christenson, Steven Deitelzweig, David E. Lanfear, Kim Marshall, Jessica Wei, and Michele Wood. All authors are members of the American College of Cardiology Accreditation Management Board. The views expressed in this paper are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. Dr. Winchester is supported by Career Development Award #13-023 from the United States Department of Veterans Affairs Health Services Research and Development Service. Dr. Peacock has received research grants from Abbott, Brainbox, CSL Behring, Ortho Clinical Diagnostics, Relypsa, Roche, Salix, and Siemens; has served as a consultant for Abbott, AstraZeneca, Beckman, Fast Biomedical, Forrest Devices, Ischemia Care, Dx, Instrument Labs, Janssen, Nabriva, Ortho Clinical Diagnostics, Osler, Relypsa, Roche, Quidel, Salix, and Siemens; and holds stock/ownership interests in AseptiScope Inc., Brainbox Inc., Comprehensive Research Associates LLC, Emergencies in Medicine LLC, Forrest Devices, and Ischemia DX LLC. Dr. Bhatt has served on the Advisory Board for Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, PLx Pharma, and Regado Biosciences; has served on the Board of Directors for the Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; has served as chair of the American Heart Association Quality Oversight Committee; the following Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi-Sankyo), and Population Health Research Institute; has received honoraria from the American College of Cardiology (ACC) (senior associate editor, Clinical Trials and News, ACC.org; vice-chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), Medtelligence/ReachMD (continuing medical education steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), and WebMD (continuing medical education steering committees), as well as Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), and VA CART Research and Publications Committee (chair); has received research funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, and The Medicines Company; has received royalties from Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); has served as site coinvestigator for Biotronik, Boston Scientific, Cardiovascular Systems, Inc., St. Jude Medical (now Abbott), and Svelte; has been a trustee for the ACC; and has provided unfunded research for FlowCo, Merck, Novo Nordisk, and Takeda. Dr. Diercks has provided institutional research for Siemens, Ortho Clinical, and Stago; and has served on the ACC Accreditation Board. Dr. Masoudi has a contract with the ACC for his role as chief scientific advisor, NCDR, and is a member (not remunerated) of the ACC Accreditation Management Board. Dr. McCord has been a consultant for Siemens and Roche; and has received research support from Roche, Beckman, and Abbott. Dr. Levy has a contract with the ACC for his role as chief medical officer, Accreditation Management Board; and has been a consultant for Siemens, Roche Diagnostics, Ortho Diagnostics, Baim Institute, and Patient Insight. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: All authors are members of the American College of Cardiology Accreditation Management Board. The views expressed in this paper are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. Dr. Winchester is supported by Career Development Award #13-023 from the United States Department of Veterans Affairs Health Services Research and Development Service. Dr. Peacock has received research grants from Abbott, Brainbox, CSL Behring, Ortho Clinical Diagnostics, Relypsa, Roche, Salix, and Siemens; has served as a consultant for Abbott, AstraZeneca, Beckman, Fast Biomedical, Forrest Devices, Ischemia Care, Dx, Instrument Labs, Janssen, Nabriva, Ortho Clinical Diagnostics, Osler, Relypsa, Roche, Quidel, Salix, and Siemens; and holds stock/ownership interests in AseptiScope Inc., Brainbox Inc., Comprehensive Research Associates LLC, Emergencies in Medicine LLC, Forrest Devices, and Ischemia DX LLC. Dr. Bhatt has served on the Advisory Board for Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, PLx Pharma, and Regado Biosciences; has served on the Board of Directors for the Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; has served as chair of the American Heart Association Quality Oversight Committee; the following Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi-Sankyo), and Population Health Research Institute; has received honoraria from the American College of Cardiology (ACC) (senior associate editor, Clinical Trials and News, ACC.org ; vice-chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), Medtelligence/ReachMD (continuing medical education steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today{\textquoteright}s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), and WebMD (continuing medical education steering committees), as well as Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), and VA CART Research and Publications Committee (chair); has received research funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, and The Medicines Company; has received royalties from Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald{\textquoteright}s Heart Disease); has served as site coinvestigator for Biotronik, Boston Scientific, Cardiovascular Systems, Inc., St. Jude Medical (now Abbott), and Svelte; has been a trustee for the ACC; and has provided unfunded research for FlowCo, Merck, Novo Nordisk, and Takeda. Dr. Diercks has provided institutional research for Siemens, Ortho Clinical, and Stago; and has served on the ACC Accreditation Board. Dr. Masoudi has a contract with the ACC for his role as chief scientific advisor, NCDR, and is a member (not remunerated) of the ACC Accreditation Management Board. Dr. McCord has been a consultant for Siemens and Roche; and has received research support from Roche, Beckman, and Abbott. Dr. Levy has a contract with the ACC for his role as chief medical officer, Accreditation Management Board; and has been a consultant for Siemens, Roche Diagnostics, Ortho Diagnostics, Baim Institute, and Patient Insight. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2020",

month = may,

day = "19",

doi = "10.1016/j.jacc.2020.03.044",

language = "English (US)",

volume = "75",

pages = "2478--2482",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "19",

}

TY - JOUR

T1 - Closing Gaps in Essential Chest Pain Care Through Accreditation

AU - Winchester, David E.

AU - Osborne, Anwar

AU - Peacock, W. Frank

AU - Bhatt, Deepak L.

AU - Dehmer, Gregory J.

AU - Diercks, Deborah

AU - Masoudi, Frederick A.

AU - McCord, James

AU - Kontos, Michael

AU - Levy, Phillip D.

N1 - Funding Information: The authors acknowledge the significant contributions of the following persons in the development of this paper and the acquisition and interpretation of accreditation data: Raymond D. Bahr, Tammy Bauer, Robert Christenson, Steven Deitelzweig, David E. Lanfear, Kim Marshall, Jessica Wei, and Michele Wood. All authors are members of the American College of Cardiology Accreditation Management Board. The views expressed in this paper are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. Dr. Winchester is supported by Career Development Award #13-023 from the United States Department of Veterans Affairs Health Services Research and Development Service. Dr. Peacock has received research grants from Abbott, Brainbox, CSL Behring, Ortho Clinical Diagnostics, Relypsa, Roche, Salix, and Siemens; has served as a consultant for Abbott, AstraZeneca, Beckman, Fast Biomedical, Forrest Devices, Ischemia Care, Dx, Instrument Labs, Janssen, Nabriva, Ortho Clinical Diagnostics, Osler, Relypsa, Roche, Quidel, Salix, and Siemens; and holds stock/ownership interests in AseptiScope Inc., Brainbox Inc., Comprehensive Research Associates LLC, Emergencies in Medicine LLC, Forrest Devices, and Ischemia DX LLC. Dr. Bhatt has served on the Advisory Board for Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, PLx Pharma, and Regado Biosciences; has served on the Board of Directors for the Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; has served as chair of the American Heart Association Quality Oversight Committee; the following Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi-Sankyo), and Population Health Research Institute; has received honoraria from the American College of Cardiology (ACC) (senior associate editor, Clinical Trials and News, ACC.org; vice-chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), Medtelligence/ReachMD (continuing medical education steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), and WebMD (continuing medical education steering committees), as well as Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), and VA CART Research and Publications Committee (chair); has received research funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, and The Medicines Company; has received royalties from Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); has served as site coinvestigator for Biotronik, Boston Scientific, Cardiovascular Systems, Inc., St. Jude Medical (now Abbott), and Svelte; has been a trustee for the ACC; and has provided unfunded research for FlowCo, Merck, Novo Nordisk, and Takeda. Dr. Diercks has provided institutional research for Siemens, Ortho Clinical, and Stago; and has served on the ACC Accreditation Board. Dr. Masoudi has a contract with the ACC for his role as chief scientific advisor, NCDR, and is a member (not remunerated) of the ACC Accreditation Management Board. Dr. McCord has been a consultant for Siemens and Roche; and has received research support from Roche, Beckman, and Abbott. Dr. Levy has a contract with the ACC for his role as chief medical officer, Accreditation Management Board; and has been a consultant for Siemens, Roche Diagnostics, Ortho Diagnostics, Baim Institute, and Patient Insight. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: All authors are members of the American College of Cardiology Accreditation Management Board. The views expressed in this paper are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. Dr. Winchester is supported by Career Development Award #13-023 from the United States Department of Veterans Affairs Health Services Research and Development Service. Dr. Peacock has received research grants from Abbott, Brainbox, CSL Behring, Ortho Clinical Diagnostics, Relypsa, Roche, Salix, and Siemens; has served as a consultant for Abbott, AstraZeneca, Beckman, Fast Biomedical, Forrest Devices, Ischemia Care, Dx, Instrument Labs, Janssen, Nabriva, Ortho Clinical Diagnostics, Osler, Relypsa, Roche, Quidel, Salix, and Siemens; and holds stock/ownership interests in AseptiScope Inc., Brainbox Inc., Comprehensive Research Associates LLC, Emergencies in Medicine LLC, Forrest Devices, and Ischemia DX LLC. Dr. Bhatt has served on the Advisory Board for Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, PLx Pharma, and Regado Biosciences; has served on the Board of Directors for the Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; has served as chair of the American Heart Association Quality Oversight Committee; the following Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi-Sankyo), and Population Health Research Institute; has received honoraria from the American College of Cardiology (ACC) (senior associate editor, Clinical Trials and News, ACC.org ; vice-chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), Medtelligence/ReachMD (continuing medical education steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), and WebMD (continuing medical education steering committees), as well as Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), and VA CART Research and Publications Committee (chair); has received research funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, and The Medicines Company; has received royalties from Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); has served as site coinvestigator for Biotronik, Boston Scientific, Cardiovascular Systems, Inc., St. Jude Medical (now Abbott), and Svelte; has been a trustee for the ACC; and has provided unfunded research for FlowCo, Merck, Novo Nordisk, and Takeda. Dr. Diercks has provided institutional research for Siemens, Ortho Clinical, and Stago; and has served on the ACC Accreditation Board. Dr. Masoudi has a contract with the ACC for his role as chief scientific advisor, NCDR, and is a member (not remunerated) of the ACC Accreditation Management Board. Dr. McCord has been a consultant for Siemens and Roche; and has received research support from Roche, Beckman, and Abbott. Dr. Levy has a contract with the ACC for his role as chief medical officer, Accreditation Management Board; and has been a consultant for Siemens, Roche Diagnostics, Ortho Diagnostics, Baim Institute, and Patient Insight. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2020/5/19

Y1 - 2020/5/19

KW - accreditation

KW - acute coronary syndrome

KW - chest pain

KW - quality of health care

UR - http://www.scopus.com/inward/record.url?scp=85084236625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084236625&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2020.03.044

DO - 10.1016/j.jacc.2020.03.044

M3 - Article

C2 - 32408982

AN - SCOPUS:85084236625

SN - 0735-1097

VL - 75

SP - 2478

EP - 2482

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 19

ER -

Closing Gaps in Essential Chest Pain Care Through Accreditation

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this